ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.

ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brad Tade - Vice President, Financial Operations Conference Call Participants Anthony Petrone - Mizuho Americas Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 08, 2024. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc. (ADMA) Q2 2024 Earnings Call Transcript

Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.

Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates

Erie Indemnity

Huntington Ingalls Industries

TreeHouse Foods

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Erie Indemnity (ERIE), TreeHouse (THS), HII (HII) and ADMA Biologics (ADMA) are well-poised to gain.

Navigate Market Turbulence With These 4 Low-Beta Stocks

ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024

In the latest trading session, Adma Biologics (ADMA) closed at $12.28, marking a +0.82% move from the previous day.

Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know

In the latest trading session, Adma Biologics (ADMA) closed at $12.18, marking a -1.46% move from the previous day.

Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights

ADMA Biologics focuses on developing and commercializing plasma-derived products, primarily targeting immune-compromised patients. Revenue streams come from FDA-approved products, immunotechnology, and CDMO services, with a promising US immunoglobulin market. The company's IP portfolio includes three FDA-approved drugs: Asceniv, Bivigam, and Nabi-HB.

ADMA Biologics: A Compelling GARP Stock For Biotech Investors

On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?

Adma Biologics (ADMA) reachead $13.05 at the closing of the latest trading day, reflecting a -1.81% change compared to its last close.

Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors

CRISPR Therapeutics

Halozyme Therapeutics

Jazz Pharmaceuticals

Vertex Pharmaceuticals

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.

Add These 5 Hot Biotech Stocks In July

Corporacion America Airports

Oceaneering

Finding millionaire-making stocks is not easy. While we can't tell the future, we can do the next best thing: think forward, gauge a company's room for growth, and determine how it intends to reach the next level.

3 Millionaire-Making Stock Picks With Astounding Growth Potential

Sezzle Inc

Super Micro Computer

The S&P 500 has had an impressive run these past 12 months. All eyes are on the Fed, anticipating a rate cut in September, and with a ‘not terrible' economy, the market could be gearing up for another upward trend.

Bull Run Alert: 3 Stocks Set to Soar in the Coming Months

Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

Adma Biologics (ADMA) reachead $11.64 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

In the most recent trading session, Adma Biologics (ADMA) closed at $10.71, indicating a +0.85% shift from the previous trading day.

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

PlayAGS

Merchants Bancorp

Northern Technologies

Strayer Education

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, NTIC, AGS, MBIN, STRA.

5 Stocks With Recent Price Strength to Tap May's Rally

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 09, 2024. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc. (ADMA) Q1 2024 Earnings Call Transcript

Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago.

Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates

1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA ( 1 ) of $26.4 Million, a 970% Increase Y-o-Y   FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million FY 2025 Net Income Guidance Increased to More than $135 Million and Adjusted EBITDA Guidance Increased to More Than $160 Million Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J.

ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update

Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.

News for ADMA Biologics Stock (ADMA)